| Bioactivity | BSJ-5-63 is a potent CDK12, CDK7, CDK9 degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer[1]. |
| Invitro | BSJ-5-63 (0-1000 nM; 8 h) 以剂量依赖性方式降低 CDK12、CDK7、CDK9、RNAPII、Cyclin K 的蛋白质表达[1]。BSJ-5-63 (0-1000 nM; 8, 16, 24 h) 以剂量和时间依赖性方式降低 BRCA1、BRCA2 的 mRNA 表达[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> BSJ-5-63 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | BSJ-5-63 (50 mg/kg; i.p.; daily for 12 days) 在小鼠中显示出抗癌活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 2519823-37-9 |
| Formula | C52H74ClN9O6S2 |
| Molar Mass | 1020.78 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gui F, et al. Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer. bioRxiv [Preprint]. 2024 Jul 10:2024.07.09.602803. |
BSJ-5-63
CAS: 2519823-37-9 F: C52H74ClN9O6S2 W: 1020.78
BSJ-5-63 is a potent CDK12, CDK7, CDK9 degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.